Week in Review: 2017 Was Record Investment Year for China Life Science; Final Week Adds $669 Million

Deals and Financings

• Shanghai's SARI was the lead investor in a $359 million acquisition of a 90% interest in Group NMS, a Milan oncology biopharma with CRO operations;
• Shanghai Henlius, a Fosun Pharma JV, raised $192 million to support its biosimilar and novel mAb operations, including $50 million from Fosun;
• LP Pharma (Xiamen) raised $30 million for its mucosa/oral controlled delivery products in a B round led by state-owned SDIC Fund Management; 
• Wenzhou Kangning Hospital plans a $30 million China IPO to expand its private psychiatric hospital offerings;
• Ch-Gemstone Capital (Beijing) invested $28.3 million via a private placement into NovaBay, a US company with anti-microbial products;
• Asieris Pharma, a China company focused on cancer, raised over $15 million in a B round for its clinical stage oral oncology drug;
• Cellular Biomedicine, a China-US biopharma, added $14.5 million of cash through private placements for its CAR-T candidate and stem cell treatments;
• Merck Serono, a subsidiary of Merck KGaA, will partner with China's Wuxi AppTec and Pontifax, an Israeli investor, to form an Israeli life science incubator;
• Walgreens Boots Alliance reduced its ownership in its China drug distribution JV with Guangzhou Pharma one month after its $420 million acquisition of a 40% stake in Sinopharm Holding's GuoDa Drug Store Company.

Stock Symbols: (SHA: 600196; HK: 2196) (HK: 2120) (NYSE: NBY) (NSDQ: CBMG) (Xetra: MRK) (NYSE: WBA)

Share this with colleagues:

Original Article: Week in Review: 2017 Was Record Investment Year for China Life Science; Final Week Adds $669 Million

More From BioPortfolio on "Week in Review: 2017 Was Record Investment Year for China Life Science; Final Week Adds $669 Million"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications